Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSH | P09668 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.41 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14491115 | 1.00 | CTSS (0.53) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL5418253 | 0.84 | SMN1; SMN2 (0.46) | CTSSCTSLSMN1; SMN2ADAM33ALDH1A1 | |
| SCHEMBL14491117 | 0.82 | CTSS (0.53) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL5443847 | 0.82 | CTSS (0.53) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL5438934 | 0.80 | CTSS (0.57) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL3023908 | 0.80 | CTSS (0.57) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL3023913 | 0.80 | CTSS (0.57) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL7159413 | 0.78 | CTSS (0.57) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL6064459 | 0.78 | CTSS (0.57) | CTSSCTSBCTSLCTSKCTSH | |
| SCHEMBL6848124 | 0.77 | CTSS (0.55) | CTSSCTSBCTSLCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | claimed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTSS 1/4885CTSB 2/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.